2026 Q2 - tulosraportti
63 päivää sitten
‧51 min
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä |
|---|---|---|
| - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastoja ja ETF:iä jotka omistavat osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q4 - tulosraportti 15.4.2027 |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 1.9. | ||
2025 Q4 - tulosraportti 15.4. | ||
2025 Q2 - tulosraportti 28.8.2025 | ||
2024 Q4 - tulosraportti 10.4.2025 | ||
2024 Q2 - tulosraportti 29.8.2024 |
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
·16 min sittenShall not advise anyone to buy because one never knows where the share price is moving, but if one has considered picking up some shares for longer-term investment then this may be the time to consider it. The share price is at approximately the average emission price level for the last 3 emissions of 750 mill that were raised and the share price has been higher a few times during the year. One must consider for oneself.
I also think this is a good long-term investment. Massive upside if they succeed. Have been in for a year now and there haven't been bad news, only progress.- ·6 t sittenwondering about this share price is heading down so it does not look good anymore ? glad I have not had more for over 100 days just had to look at this stock hoped it was at price 15 kr. now but no heading down to 20 øre maybe
- ·11 t sitten · MuokattuFocus on development vs results has for a long time been the way the most skilled professionals across all industries work. Circio works methodically with development. Small steps all the way towards the final platform that will be able to change gene therapy. Circio – technology status Documented technology: circVec: Circular RNA with significantly longer half-life than traditional mRNA. Heart: circVec 5.2 shows approx. 200x higher gene expression, 95% heart specificity and under 1% expression in liver. CNS/brain: Up to 60x higher gene expression. Eye: Documented improved gene expression and tissue specificity. In vivo CAR-T: Technology to produce CAR-T cells directly in the body. Next components they are working on: Disease models for heart and eye. Results from CNS collaboration with top-5 pharma. Optimization of circVec generation 5. Finalizing LNP delivery to T cells. Documenting effective in vivo CAR-T. Choosing first concrete drug candidates. Short summary: The technology is documented preclinical. Now Circio will prove therapeutic effect and make the platform ready for commercial partnership agreements.
Well they have something to prove first then. Without concrete and solid evidence, they have nothing tangible to point to. Then it's just maybe, if and possibly. That is not enough for any rise in the share price. We have seen that up to now. 
·11 t sitten · MuokattuThrough my experience and follow-up of this industry, I have learned that RNA and gene therapy companies can have an enormous potential, and that the picture can change quickly when positive research results arrive. We have seen it with Moderna, and we have seen companies like Orbital Therapeutics and Capstan Therapeutics attract great interest from large pharma companies and be acquired for billion-dollar amounts. Therefore, I believe that we should not spend time on negative comments or daily noise in the forum. I choose instead to see the big picture, follow technology development, and assess the actual results and the company's future opportunities. My experience is that the market does not always discover the company's true value in time. Sometimes the big change comes when most people least expect it. I choose to focus on the opportunities and results, not fear and pessimism. The future can bring big surprises! 💪🏆
You mention 3 companies that have had great success, you can perhaps in the same breath also mention plenty of such that have gone under...?
·12 t sittenHas a date been communicated for when the results from the collaboration with Big Pharma will be launched?
They expect publication of data during the first half of 2027, hopefully early 2027. Wiklund has communicated that there is a bit of paperwork and other stuff that needs to be in place, and that BP has its requirements that Circio must relate to. Therefore, the data will be published on BP's terms. In return, it has been clearly communicated that the intention is a transaction in the form of a licensing agreement, and that this will be finally agreed and stock exchange announced shortly after publication of the data, given that everything goes as it should. I believe that negotiations regarding the licensing agreement/transaction are taking place in parallel with the studies, and that this may be part of the reason why the data is only coming next year and not before Christmas as Wiklund has mentioned earlier. BP likely wants news about data and collaboration to be published around the same time.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tuotteita joiden kohde-etuutena tämä arvopaperi
Välittäjätilasto
Dataa ei löytynyt
2026 Q2 - tulosraportti
63 päivää sitten
‧51 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
- ·16 min sittenShall not advise anyone to buy because one never knows where the share price is moving, but if one has considered picking up some shares for longer-term investment then this may be the time to consider it. The share price is at approximately the average emission price level for the last 3 emissions of 750 mill that were raised and the share price has been higher a few times during the year. One must consider for oneself.I also think this is a good long-term investment. Massive upside if they succeed. Have been in for a year now and there haven't been bad news, only progress.
- ·6 t sittenwondering about this share price is heading down so it does not look good anymore ? glad I have not had more for over 100 days just had to look at this stock hoped it was at price 15 kr. now but no heading down to 20 øre maybe
- ·11 t sitten · MuokattuFocus on development vs results has for a long time been the way the most skilled professionals across all industries work. Circio works methodically with development. Small steps all the way towards the final platform that will be able to change gene therapy. Circio – technology status Documented technology: circVec: Circular RNA with significantly longer half-life than traditional mRNA. Heart: circVec 5.2 shows approx. 200x higher gene expression, 95% heart specificity and under 1% expression in liver. CNS/brain: Up to 60x higher gene expression. Eye: Documented improved gene expression and tissue specificity. In vivo CAR-T: Technology to produce CAR-T cells directly in the body. Next components they are working on: Disease models for heart and eye. Results from CNS collaboration with top-5 pharma. Optimization of circVec generation 5. Finalizing LNP delivery to T cells. Documenting effective in vivo CAR-T. Choosing first concrete drug candidates. Short summary: The technology is documented preclinical. Now Circio will prove therapeutic effect and make the platform ready for commercial partnership agreements.Well they have something to prove first then. Without concrete and solid evidence, they have nothing tangible to point to. Then it's just maybe, if and possibly. That is not enough for any rise in the share price. We have seen that up to now.
- ·11 t sitten · MuokattuThrough my experience and follow-up of this industry, I have learned that RNA and gene therapy companies can have an enormous potential, and that the picture can change quickly when positive research results arrive. We have seen it with Moderna, and we have seen companies like Orbital Therapeutics and Capstan Therapeutics attract great interest from large pharma companies and be acquired for billion-dollar amounts. Therefore, I believe that we should not spend time on negative comments or daily noise in the forum. I choose instead to see the big picture, follow technology development, and assess the actual results and the company's future opportunities. My experience is that the market does not always discover the company's true value in time. Sometimes the big change comes when most people least expect it. I choose to focus on the opportunities and results, not fear and pessimism. The future can bring big surprises! 💪🏆You mention 3 companies that have had great success, you can perhaps in the same breath also mention plenty of such that have gone under...?
- ·12 t sittenHas a date been communicated for when the results from the collaboration with Big Pharma will be launched?They expect publication of data during the first half of 2027, hopefully early 2027. Wiklund has communicated that there is a bit of paperwork and other stuff that needs to be in place, and that BP has its requirements that Circio must relate to. Therefore, the data will be published on BP's terms. In return, it has been clearly communicated that the intention is a transaction in the form of a licensing agreement, and that this will be finally agreed and stock exchange announced shortly after publication of the data, given that everything goes as it should. I believe that negotiations regarding the licensing agreement/transaction are taking place in parallel with the studies, and that this may be part of the reason why the data is only coming next year and not before Christmas as Wiklund has mentioned earlier. BP likely wants news about data and collaboration to be published around the same time.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä |
|---|---|---|
| - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastoja ja ETF:iä jotka omistavat osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q4 - tulosraportti 15.4.2027 |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 1.9. | ||
2025 Q4 - tulosraportti 15.4. | ||
2025 Q2 - tulosraportti 28.8.2025 | ||
2024 Q4 - tulosraportti 10.4.2025 | ||
2024 Q2 - tulosraportti 29.8.2024 |
Tuotteita joiden kohde-etuutena tämä arvopaperi
Välittäjätilasto
Dataa ei löytynyt
2026 Q2 - tulosraportti
63 päivää sitten
‧51 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q4 - tulosraportti 15.4.2027 |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 1.9. | ||
2025 Q4 - tulosraportti 15.4. | ||
2025 Q2 - tulosraportti 28.8.2025 | ||
2024 Q4 - tulosraportti 10.4.2025 | ||
2024 Q2 - tulosraportti 29.8.2024 |
Tuotteita joiden kohde-etuutena tämä arvopaperi
Foorumi
Liity keskusteluun Nordnet Socialissa
- ·16 min sittenShall not advise anyone to buy because one never knows where the share price is moving, but if one has considered picking up some shares for longer-term investment then this may be the time to consider it. The share price is at approximately the average emission price level for the last 3 emissions of 750 mill that were raised and the share price has been higher a few times during the year. One must consider for oneself.I also think this is a good long-term investment. Massive upside if they succeed. Have been in for a year now and there haven't been bad news, only progress.
- ·6 t sittenwondering about this share price is heading down so it does not look good anymore ? glad I have not had more for over 100 days just had to look at this stock hoped it was at price 15 kr. now but no heading down to 20 øre maybe
- ·11 t sitten · MuokattuFocus on development vs results has for a long time been the way the most skilled professionals across all industries work. Circio works methodically with development. Small steps all the way towards the final platform that will be able to change gene therapy. Circio – technology status Documented technology: circVec: Circular RNA with significantly longer half-life than traditional mRNA. Heart: circVec 5.2 shows approx. 200x higher gene expression, 95% heart specificity and under 1% expression in liver. CNS/brain: Up to 60x higher gene expression. Eye: Documented improved gene expression and tissue specificity. In vivo CAR-T: Technology to produce CAR-T cells directly in the body. Next components they are working on: Disease models for heart and eye. Results from CNS collaboration with top-5 pharma. Optimization of circVec generation 5. Finalizing LNP delivery to T cells. Documenting effective in vivo CAR-T. Choosing first concrete drug candidates. Short summary: The technology is documented preclinical. Now Circio will prove therapeutic effect and make the platform ready for commercial partnership agreements.Well they have something to prove first then. Without concrete and solid evidence, they have nothing tangible to point to. Then it's just maybe, if and possibly. That is not enough for any rise in the share price. We have seen that up to now.
- ·11 t sitten · MuokattuThrough my experience and follow-up of this industry, I have learned that RNA and gene therapy companies can have an enormous potential, and that the picture can change quickly when positive research results arrive. We have seen it with Moderna, and we have seen companies like Orbital Therapeutics and Capstan Therapeutics attract great interest from large pharma companies and be acquired for billion-dollar amounts. Therefore, I believe that we should not spend time on negative comments or daily noise in the forum. I choose instead to see the big picture, follow technology development, and assess the actual results and the company's future opportunities. My experience is that the market does not always discover the company's true value in time. Sometimes the big change comes when most people least expect it. I choose to focus on the opportunities and results, not fear and pessimism. The future can bring big surprises! 💪🏆You mention 3 companies that have had great success, you can perhaps in the same breath also mention plenty of such that have gone under...?
- ·12 t sittenHas a date been communicated for when the results from the collaboration with Big Pharma will be launched?They expect publication of data during the first half of 2027, hopefully early 2027. Wiklund has communicated that there is a bit of paperwork and other stuff that needs to be in place, and that BP has its requirements that Circio must relate to. Therefore, the data will be published on BP's terms. In return, it has been clearly communicated that the intention is a transaction in the form of a licensing agreement, and that this will be finally agreed and stock exchange announced shortly after publication of the data, given that everything goes as it should. I believe that negotiations regarding the licensing agreement/transaction are taking place in parallel with the studies, and that this may be part of the reason why the data is only coming next year and not before Christmas as Wiklund has mentioned earlier. BP likely wants news about data and collaboration to be published around the same time.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä |
|---|---|---|
| - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastoja ja ETF:iä jotka omistavat osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Välittäjätilasto
Dataa ei löytynyt